<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03677011</url>
  </required_header>
  <id_info>
    <org_study_id>100006555</org_study_id>
    <nct_id>NCT03677011</nct_id>
  </id_info>
  <brief_title>Andrositol® TEST as Diagnostic Assay to Predict the Fertilization Potential in IVF</brief_title>
  <official_title>Andrositol® TEST as Diagnostic Assay to Predict the Fertilization Potential of the Sperm in the in Vitro Fertilization (IVF) Procedures.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lo.Li.Pharma s.r.l</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lo.Li.Pharma s.r.l</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Andrositol® test allows to obtain additional information besides the WHO parameters and to
      evaluate the semen energetic status. The diagnosis is performed by analyzing the semen at two
      different time points: before the treatment and 30' after the addiction of myo-inositol
      directly to the semen. The purpose of this study is to evaluate if the responsiveness to the
      Andrositol® test of a sperm sample can be predictive of its fertilization rate in an ICSI
      (Intracytoplasmic Sperm Injection) cycle (primary outcome). Secondary outcomes as embryo
      development, embryo euploidy status and embryo implantation rate will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>increment of the fertilization rate</measure>
    <time_frame>up to 20 hours after ICSI</time_frame>
    <description>measurement of the % oocytes become fertilized by sperm cells. This outcome, is calculated for each patient at day + 1 (14-20h after icsi)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increment of implantation rate</measure>
    <time_frame>up to 10 days after ICSI</time_frame>
    <description>implantation rate is calculated as the number of gestational sacs observed at echographic screening at +5 weeks of pregnancy divided by the number of embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>embryo development</measure>
    <time_frame>up to 6 days after ICSI</time_frame>
    <description>the number of blastocysts for each patient at day +5, +6, +7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>embryo euploidy</measure>
    <time_frame>from 10 days after ICSI</time_frame>
    <description>Embryo euploidy for each patient at day +10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Male Infertility</condition>
  <arm_group>
    <arm_group_label>category 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Low responder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>category 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Medium Responder and High Responder</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Andrositol® Test</intervention_name>
    <description>The intervention consists in the addiction of myo-inositol directly to the semen identifying the quality of sperm prior ICSI procedure</description>
    <arm_group_label>category 1</arm_group_label>
    <arm_group_label>category 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male partners of couples undergoing an egg donor cycles

        Exclusion Criteria:

          -  sperm volume lower than 1 ml

          -  sperm count lower than 5 X 106 /ml

          -  total sperm motility lower than 10%
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Since we are testing the predictive value of a sperm test, the gender of the prospective subjects will be restricted to male partners of couples undergoing an ICSI treatment.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tih T. Tan, Ms</last_name>
    <role>Principal Investigator</role>
    <affiliation>HRC Pasadena 333 S Arroyo Pkwy Fl 3 Pasadena, CA 91105</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tih T. Tan, Ms</last_name>
    <phone>(626) 440-9161</phone>
    <email>TihT@havingbabies.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HRC Pasadena</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tih Tan, Ms</last_name>
      <phone>626-440-9161</phone>
      <email>TihT@havingbabies.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myo-inositol</keyword>
  <keyword>fertilization rate</keyword>
  <keyword>infertility</keyword>
  <keyword>Intracytoplasmic Sperm Injection</keyword>
  <keyword>sperm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

